Loading...
Loading...
Agomab Therapeutics NV
Agomab Therapeutics NV. Spoken Alpha tracks AGMB's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks AGMB's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 9/10 quarters but stock falls 80% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for AGMB.
curl https://api.spokenalpha.com/v1/companies/AGMB| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.17 | $1.06 | +10.0% | -2.8% | -1.9% |
| Q4 FY2026 | $1.30 | $1.16 | +12.2% | -4.0% | -2.6% |
| Q3 FY2026 | $1.28 | $1.30 | -1.3% | -8.8% | -7.4% |
| Q2 FY2026 | $1.11 | $1.08 | +2.8% | -7.0% | -8.0% |
| Q1 FY2025 | $1.45 | $1.35 | +7.6% | +0.4% | -0.9% |
| Q4 FY2025 | $1.50 | $1.37 | +9.8% | -1.6% | -2.7% |
| Q3 FY2025 | $1.40 | $1.35 | +3.8% | -3.3% | -0.5% |
| Q2 FY2025 | $1.34 | $1.19 | +13.0% | +2.4% | +1.3% |
| Q1 FY2024 | $1.27 | $1.24 | +2.1% | -8.5% | -8.9% |
| Q4 FY2024 | $1.42 | $1.37 | +3.9% | -2.0% | -2.0% |